Children have higher rates of virological failure than adults, often associated with more extensive resistance and limited second-line options. In order to maintain clinical benefits of highly active antiretroviral therapy (HAART) into adulthood, particularly for children starting at a young age, strategies are needed to limit the emergence of resistance and to offer highly effective subsequent lines of therapy. Similarly, well resourced settings face challenges regarding extensive resistance accumulated over the past decade or more, particularly resulting from suboptimal therapies.
Introduction
Highly active antiretroviral therapy (HAART) has demonstrated impressive reductions in morbidity and mortality in children [1] [2] [3] [4] [5] . According to international guidelines [6] [7] [8] , the treatment of choice for HIV-1-infected children and adults is a combination of two nucleoside reversetranscriptase inhibitors (NRTIs) (backbone treatment) and a third agent from a different class, either a nonnucleoside reverse-transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor. Although there are currently 21 US Food and Drug Administration (FDA)approved antiretrovirals (ARVs) available for use in the treatment of HIV-infected adults and adolescents, only 14 of these drugs are approved for use in children, and 13 of these are available in paediatric formulations (Table 1) .
Children, and infants in particular, are a unique population with regards to HIV infection; they are at greater risk of developing resistance for a number of reasons.
First, younger children have higher viral loads [9, 10] as compared to adolescents and adults. Second, there are challenges to accurate dosing, particularly in smaller children, due to formulation limitations increasing the potential for subtherapeutic drug concentrations, viral replication and resistance. In a UK cohort study, children were found to be underdosed for 6-62% of patient-time at risk [11] . Failure to account for ongoing growth and failure to adjust dosing following changes to recommendations were cited as important contributors to the underdosing. Third, there is a complex landscape of psychosocial factors that affect adherence to medication throughout childhood and into adolescence.
Unsurprisingly perhaps, studies have demonstrated only modest virological responses to HAART in children [12] ; a recent large multicentre European cohort collaboration study reported a lower probability of virological response in children aged 6-12 years (adjusted hazard ratio 0.87) and 13-17 years (0.78) after starting first-line HAART, compared with adults [13 ] (note children <6 years of age were not included in the study). Although the prevalence of resistance at viral failure following first-line therapy has not been directly compared between adults and children, small studies from resource-poor settings suggest that the emergence of resistance at viral failure is similar in children and adults when NNRTI is used as the third agent [14,15 ,16,17,18 ,19 ] . In the context of higher viral failure rates, particularly in younger children [14,15 ,19 ] , this translates into higher resistance in the paediatric population as a whole.
Resistance is a greater challenge in children, as they require longer-term therapy as compared to adults. Any analysis of paediatric HIV-1 resistance needs to address two groups; first, those patients in high-income and middle-income countries where there is access to frequent viral load monitoring, genotypic resistance testing (GRT) and a greater range of ARVs including investigational agents. The second group in the resource-poor world bears the vast majority of global HIV-1 disease burden; these patients generally have no or very limited viral monitoring or GRT, and ARV options are limited to two lines at most (presently not including tenofovir). In this review, we explore current knowledge of resistance in diverse settings, sequencing of regimens including salvage, use of resistance testing, management of transmitted resistance and prevention of mother-to-child transmission (PMTCT) associated resistance.
Resistance following first-line nonnucleoside reverse-transcriptase inhibitor containing highly active antiretroviral therapy
First-line HAART consisting of a thymidine analogue, lamivudine (3TC) and nevirapine (NVP) or efavirenz (EFV) is used in the vast majority of children worldwide, due to availability of cheap generic fixed dose combinations (FDCs). In particular, stavudine (d4T), 3TC and NVP are used, with the advantage of WHO-approved child and infant FDC preparations (Pedimune Junior and Pedimune Baby), which have a higher concentration of NVP in relation to NRTIs compared with their adult counterparts. In Cambodia [18 ] , high rates of resistance have been found in patients with a median age of 6 who were failing ART (mainly d4T, 3TC and NVP in adult formulations); after 1 year, 76% had M184V conferring high-level resistance to lamivudine, 94% had high-level NNRTI resistance, 11% acquired K65R conferring resistance to all NRTI except zidovudine (AZT), and 11% developed L74V conferring resistance to abacavir (ABC) and didanosine (ddI). Similar resistance to lamivudine and NNRTI has also been seen in Thai and West African studies [15 ,16,19 ] , although prevalence of K65R and L74V was lower. These findings are similar to those found in adults under similar monitoring conditions [20, 21 ] . It is becoming apparent that stavudine selects K65R, L74V and Q151M [15 ,20,21 ] , contributing to broad NRTI resistance in a proportion of patients who are not monitored by 3 monthly HIV-1 RNA viral load testing. Notably, the evidence that tenofovir (TDF) loses activity in the face of any of these mutations is weak, and largely based on in-vitro phenotypic data rather than clinical response data. Unfortunately, tenofovir is expensive and not currently available as second line in most parts of the developing world. Furthermore, it is not yet licensed for children (phase II trial ongoing), although it is increasingly being used as a salvage drug or as part of Truvada for first-line ART when adult doses can be used in adolescents.
We can conclude therefore that most patients failing NNRTI-based HAART in developing world settings will have high-level resistance to lamivudine and NNRTI. The recommended second-line regimen of ddI/ABC or AZT/boosted protease inhibitor should have durable potency in the majority; those with multinucleoside mutations might gain more durable antiviral impact with TDF and AZT. This is due to the fact that K65R confers hypersusceptibility to AZT and bi-directional antagonism exists between thymidine analogue mutations normally selected by AZT [22] and K65R. The currently approved protease inhibitors for children include lopinavir (LPV), amprenavir (APV), fosamprenavir (fAPV), ritonavir (RTV), nelfinavir (NFV) and tipranavir (TPV). Darunavir (DRV) in children older than 6 years is currently under consideration by the FDA/European Medicines Agency (EMEA). As in the case of adults, ritonavir is no longer used alone; instead, it is used to 'boost' other protease inhibitors by virtue of its potent inhibition of CYP3A4. Boosted atazanavir (ATV) has been used as part of a simplification strategy in protease inhibitor experienced adolescents, but investigators found high rates of virologic failure in those who switched from LPV to ATV [23] . NFV was historically used unboosted, and its use is declining. Difficulties in boosting with separate ritonavir (syrup very unpleasant in taste and 100 mg capsules large) means that in reality only Kaletra (lopinavir and ritonavir combined) is frequently used in preadolescent children.
There are few studies of first-line NNRTI-based HAART in children from settings with viral load monitoring and resistance testing. Mullen et al. [24] studied eight children failing NVP-based HAART and six (75%) developing one or more of the K103N, Y181C or G190A mutations. Similarly, Agwu et al. [25 ] found 80% NNRTI resistance in adolescents on first-line HAART for a median of 102 weeks. These rates are higher than those in adults and probably reflect the delay in switching. In fact, they are similar to resistance rates seen in settings without viral load monitoring, where prolonged virological failure also occurs. Given there is often significant time on a failing regimen, it is important that resistance testing is undertaken as close to the time of switch as possible and that previous resistance test results are also taken into account when deciding on a new regimen.
Resistance following first-line protease inhibitor containing highly active antiretroviral therapy
Resistance profiles at first-line protease inhibitor failure are determined both by the protease inhibitor used, as well as whether ritonavir boosting was used [26] . Certain agents select signature mutations in protease, for example D30N by nelfinavir, I50L by atazanavir and G48V by saquinavir. Other mutations at positions such as 46, 82, 84 and 90 can be selected by multiple protease inhibitors (Table 1) .
Unboosted protease inhibitors, especially nelfinavir, continue to be used as first-line protease inhibitor, and much of the existing historical data comes from children treated with this agent; this is of importance, as choice of HAART regimens need to be considered in the context of nelfinavir-related resistance, most commonly D30N and L90M. Evidence from adult studies shows that major protease inhibitor mutations are rare following viral failure of ritonavir boosted protease inhibitors, in contrast to unboosted protease inhibitors [26, 27 ] .
Among the 269 HIV-1-infected children enrolled in the ANRS 1278 prospective observational cohort [16] There is evidence from adults that first-line boosted protease inhibitors may lead to lower rates of resistance both to the protease inhibitor itself and to other concomitant ARVs; ACTG 5142 [31 ] and a recent metaanalysis demonstrate that M184V, conferring resistance to lamivudine, and K65R are less common in adults treated with boosted protease inhibitor as opposed to NNRTI-based HAART. Agwu et al. [25 ] reported similar findings in adolescents and if these observations hold true in younger children, first-line boosted protease inhibitors may be beneficial in poorer adherers, given that the plasma half-lives of NRTI and protease inhibitors are similar. Resource-poor settings where drug supplies are erratic and socioeconomic conditions are difficult may also favour such an approach, although this must be balanced against the need for HAART regimens which can be used safely and effectively with anti-TB treatment, and the considerable issues around formulations (Kaletra liquid is expensive, requires refrigeration and is poorly tolerated; Kaletra paediatric tablets are relatively large and cannot be broken due to loss of bioavailability).
Second-line boosted protease inhibitor based therapy following failure of first-line protease inhibitor therapy
There are studies in protease inhibitor experienced children (usually NFV) demonstrating reasonable virological responses to regimens containing LPV/ritonavir [32, 33] , although increasing numbers of previous regimens and resistance mutations reduces response rates to subsequent protease inhibitors. This highlights the potential importance of taking into account GRT and treatment history (including possible in-utero ARV exposure) when deciding on subsequent lines of ART.
Nucleoside reverse-transcriptase inhibitor backbones in first-line highly active antiretroviral therapy
Thymidine analogues have been used widely as part of the public health approach to ART, mainly as a result of cheap fixed-dose combinations. However, these agents may not be ideal in terms of resistance profiles. PENTA 5 was a randomized comparison between ABC/3TC, AZT/ 3TC and ABC/AZT with or without NFV. Virological response to ABC/3TC was superior to that to ABC/AZT and AZT/3TC, although there was a greater prevalence of resistance to ABC and 3TC with the former regimen [34] . This study also showed no difference in resistance according to subtype [35] , although numbers were small. A randomized study into ABC as part of triple nucleoside HAART or with NNRTI is underway in Uganda and Zimbabwe.
Salvage therapies
Salvage has classically applied to patients who have failed multiple lines of HAART. Regardless of the first-line and second-line, in most circumstances, the patient will have been exposed to NRTI, NNRTI as well as protease inhibitor (perhaps unboosted). GRT is important in such circumstances, as long as agents from existing as well as new classes are available. In resource-poor settings, GRT is likely to have limited use in the absence of secondgeneration protease inhibitors.
Second-generation protease inhibitors
Although second-generation ritonavir-boosted protease inhibitors have been licensed in adults recently, there are few data in children. Salazar et al. [36 ] conducted a trial of high-dose and low-dose ritonavir-boosted tipranavir in mainly experienced patients with viral loads above 1500 copies/ml, in combination with an optimized background regimen which did not include CCR5 antagonists or integrase inhibitors. Thirteen per cent of the patients received enfurvitide. Nearly half of them were aged 12 and above, with 22% aged 2-6 years and 33% aged 6-12. Median number of previous drugs was seven, and half of the patients exhibited resistance to all protease inhibitors with a similar proportion having a Genotypic Sensitivity Score (GSS) (the sum of the genotypically sensitive background drugs as determined by a scoring algorithm) of zero. Both oral solutions and capsules were available. At 48 weeks, 39.7% low-dose and 45.6% high-dose TPV/ritonavir recipients had viral load less than 400 copies/ml and 34.5 and 35.1%, respectively, achieved viral load less than 50 copies/ml. There was a trend toward improved virological success using the higher dose in older children who also had lower GSS and poorer adherence. Genotypic inhibitory quotient (GIQ), a composite of the TPV mutation score [37] and trough drug levels strongly predicted virological failure, and resistance profiles in those failing therapy were reported to be similar to those found in the adult RESIST studies. The following 21 mutations at 16 positions have been identified as contributing to TPV resistance: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D and 84V [37] .
The other second-generation protease inhibitor, darunavir, was recently studied in a total of 80 heavily treatmentexperienced children [38 ] . Median age was 14 years with a median of nine previous ARVs. Darunavir/ritonavir was dosed according to weight. Optimized background therapy (OBT) was added on the basis of genotypic resistance testing, although very few were given the fusion inhibitor enfurvitide. After 48 weeks, by intentto-treat analysis viral load fell below 400 copies/ml in 59% and below 50 copies/ml in 48%. Response rates were reduced by the number of preexisting darunavir-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L,  I54M , G73S, L76V, I84V and L89V): viral load suppression to below 50 copies/ml was achieved in 59% of those with no darunavir resistance mutations at baseline, 47% of those with one or two and none of those with three or more. As with TPV, mean increases in CD4 cell counts were impressive, and darunavir drug exposure levels were comparable to those seen in adults. Results may not be as good as expected, potentially due to difficulties adhering to separately dosed ritonavir (as syrup or 100 mg capsules), the lack of a second highly effective agent in the regimen and the limited use of EFV as part of OBT in these studies.
Dual boosted protease inhibitor therapy
A dual-boosted protease inhibitor strategy has been studied by Kosalaraksa et al. [39 ] in patients failing standard NRTI/NNRTI regimens in the absence of resistance testing and access to second-generation protease inhibitor. They conducted a study in Thailand in 50 children and used dual boosted protease inhibitor therapy with SQV and LPV together with low-dose ritonavir. At 48 weeks, the median CD4% rise was nine [interquartile range (IQR) 5-16] and median HIV RNA reduction was À2.8 log10 (IQR À3.2 to À1.4), both P < 0.001. Thirtynine (78%) and 32 (64%) children had viral load less than 400 and less than 50 copies/ml. Five children (10%) had viral load failure associated with poor adherence and no major protease inhibitor mutations were seen. Median serum cholesterol and triglyceride increased significantly and mean minimum plasma concentrations (C min ) of LPV and SQV were well above the therapeutic level. Robbins et al. [40 ] have demonstrated the safety of high-dose LPV/ritonavir (400/100 mg)/m 2 in combination with saquinavir in 16 treatment-experienced children with median age of 15 years, albeit with modest virological outcomes. Dual boosted protease inhibitor could be used in patients with extensive NRTI resistance, although further efficacy data are needed to establish whether this strategy offers significant advantage over boosted LPV.
Resistance testing
Genotypic resistance testing following virological failure in adults has been shown to lead to modest virological benefits [41, 42] . PENTA 8 [43] was a randomized trial of GRT vs clinician-guided switch in virologically failing children, and this study showed no virological or immunological benefit at 96 weeks. However, this finding should be interpreted with caution, as second-generation protease inhibitors and tenofovir were not available. In the absence of highly potent subsequent lines of therapy, GRT would not be expected to show virological benefit in patients with extensive resistance.
Indirect evidence for the potential utility of GRT comes from retrospective salvage studies where response can be related to the number of protease inhibitor mutations at baseline. In 45 triple class experienced patients, Ramos et al. [33] had an intention-to-treat response rate of 42% achieving viral load less than 400 copies/ml using LPV/ ritonavir in combination with OBT. Nonresponders had 7.0 protease inhibitor associated mutations at baseline compared with 4.8 in children achieving virologic suppression (P ¼ 0.06). Delaugerre et al. [29] found that viral failure with LPV was significantly higher when the children were previously treated with protease inhibitors and when the baseline LPV mutation score exceeded three mutations. GRT could be used in such patients to predict probability of response to boosted protease inhibitor in those with unboosted protease inhibitor experience. In the context of availability of secondgeneration protease inhibitors, GRT may have a use in deciding which children are treated with TPV vs DRV, as both have a different susceptibility scoring system based on GRT in adults.
Limitations of population GRT include the fact that minority species are not detected below a threshold of 20-30%. Studies suggest that GRT underestimates the prevalence of resistant species by as much as 50% [44] [45] [46] , although the clinical impact of this is less clear. A further potential limitation pertains to failure with protease inhibitor. It is increasingly appreciated that mutations in the protease substrate, Gag, can also lead to resistance and/or restoration of replicative capacity [47, 48] , and have been seen in the absence of protease mutations [49] . Currently, gag is not sequenced and therefore this information is not available to estimate an isolate's susceptibility to protease inhibitor. Resistance encoded in gag may be important following failure of boosted protease inhibitor, where major protease mutations are rarely seen.
Larru et al. [50] recently assessed the utility of virtual phenotype resistance testing by performing a retrospective analysis of heavily experienced children with median age 15 years who had at least 6 months follow-up after initiating salvage therapy. The patients with virological response had a mean number of susceptible drugs according to the lower clinical cut-off of 1.7 vs 0.8 (P ¼ 0.03) in those who did not have a response; for the upper clinical cut-off, the predicted mean number of susceptible drugs was 2.7 vs 1.3 (P ¼ 0.01). These data reinforce current consensus that patients should be switched for treatment failure when there are at least two agents to which the virus is fully susceptible. However, it should be noted that virtual phenotype suffers similar limitations regarding minority resistant species when based on population sequencing data.
Transmitted resistance
In developing world settings, the prevalence of transmitted resistance is still low [51 ,52] . However, this seems to be changing in middle-income and highincome countries. Studies from Brazil and Argentina [53, 54 ] 
Prevention of resistance and prevention of mother-to-child transmission
Ultimately, management of resistance in children should be aimed at prevention. Effective PMTCT with HAART can reduce vertical transmission to 2% or less (in both well resourced settings [56] and resource-poor settings [57] ) using NNRTI-based regimens. Unfortunately, in the latter setting, PMTCT is often still in the form of single-dose NVP, despite higher transmission rates and updated WHO guidelines [58] .
Resistance in infants exposed to single-dose NVP has been extensively studied, and the prevalence at 4-8 weeks postpartum estimated in a recent metaanalysis at 52.6% [95% confidence interval (CI) 37.7-67.0]. Addition of short course antenatal/intrapartum zidovudine þ lamivudine and/or postpartum zidovudine and lamivudine and/or postnatal zidovudine and lamivudine reduced the incidence of resistance to 16.5% (95% CI 8.9-28.3) [59 ] in the same analysis. HAART during pregnancy offers the best chance of reducing both transmission and resistance in children.
Transmission of HIV infection through breastfeeding is estimated at 10% [60] . Extended prophylaxis with 6 weeks of NVP reduces breast milk associated transmission by around 50% [61 ,62 ] . In those infants infected in the first 6 weeks of life despite this strategy, the likelihood of NVP resistance has been found to be increased compared with those children who had received sdNVP alone -92 vs 38% [63] and 84 vs 50% [64 ] in two recent studies.
The CHER trial conducted in South Africa [65 ] showed that early treatment of infants with boosted protease inhibitors reduced early infant mortality by 76% and HIV progression by 75%. As many of these infants will have been exposed to single-dose NVP and have high-level resistance to NNRTI, use of protease inhibitor is appropriate and now recommended by WHO for first-line treatment during infancy following perinatal NVP exposure. Issues remain about how best to use Kaletra in infants, which probably requires higher doses than in adults. The use of boosted protease inhibitor in infants and increasing numbers of patients switching to second line signals an increase in the use of protease inhibitors in resourcepoor settings. Although such regimens are currently costly, generic production of combined protease inhibitor/ritonavir is underway. However, more data are needed on the response to boosted protease inhibitor in subtypes prevalent in sub-Saharan Africa, such as A, D and C.
Conclusion
There are specific challenges in treating HIV-infected children, including uncertainty about the best time to start treatment, the need for more paediatric formulations, the lack of pharmacokinetic studies for new drugs and incomplete dosing guidelines. Furthermore, the most appropriate regimen depends on a variety of factors, including the age, appropriate drug formulations, the potency, dosing and toxicity.
The combination of these factors makes resistance in children a far more challenging problem. Tenofovir retains activity in a number of resistant strains but is currently not licensed in children due to concerns regarding skeletal toxicity. It is being used in older children, however, due to a lack of alternative agents. Trials using second-generation NNRTI such as etravirine, CCR5 antagonists and integrase inhibitors are urgently needed. Further work on optimal sequencing of regimens is also fundamental to the management of antiretroviral therapy. Future agents targeting viral maturation, those using RNA interference and therapeutic vaccines should also be developed with treatment of paediatric HIV in mind. This very important trial of early vs deferred HAART in infants showed a mortality benefit for the former group. WHO guidelines were changed as a result of this study.
